Evidence map›Paper›PMID 26331993›Full record

ReviewSmall (Weinheim an der Bergstrasse, Germany)2015

Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.

Ronnie H Fang, Ashley V Kroll, Liangfang Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Small (Weinheim an der Bergstrasse, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Stem Cell's Secretome Delivery Systems.Advanced pharmaceutical bulletin · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ronnie H FangDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Ashley V KrollDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
Liangfang ZhangDepartment of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.

Funding

Innate Antimicrobial Nanotherapeutics for the Treatment of H. pylori InfectionR01DK095168 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHANG, LIANGFANG · 2012 to 2016
$1.6M
Chemical Biology Interfaces at UC San DiegoT32GM112584 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BURKART, MICHAEL D. · 2015 to 2019
$729k
NIDDK NIH HHS R01 DK095168NIDDK NIH HHS R01DK095168NIGMS NIH HHS T32 GM112584
6 · The paper itself

Abstract

Immunotherapeutic approaches for treating cancer overall have been receiving a considerable amount of interest due to the recent approval of several clinical formulations. Among the different modalities, anticancer vaccination acts by training the body to endogenously generate a response against tumor cells. However, despite the large amount of work that has gone into the development of such vaccines, the near absence of clinically approved formulations highlights the many challenges facing those working in the field. The generation of potent endogenous anticancer responses poses unique challenges due to the similarity between cancer cells and normal, healthy cells. As researchers continue to tackle the limited efficacy of vaccine formulations, fresh and novel approaches are being sought after to address many of the underlying problems. Here the application of nanoparticle technology towards the development of anticancer vaccines is discussed. Specifically, there is a focus on the benefits of using such strategies to manipulate antigen presenting cells (APCs), which are essential to the vaccination process, and how nanoparticle-based platforms can be rationally engineered to elicit appropriate downstream immune responses.

Indexed as

AnimalsAntigen-Presenting CellsCancer VaccinesHumansImmunotherapy, AdoptiveNanocapsulesNeoplasmsCancer VaccinesNanocapsulesantigen presentationcancer immunotherapycancer vaccinesimmunoengineeringnanomedicine

Identifiers

PMID26331993
PMCPMC4641138

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.